These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 16100349)

  • 1. Increase in methotrexate dose in patients with rheumatoid arthritis who have an inadequate response to infliximab.
    Ornetti P; Solau E; Gaudin P; Sibilia J; Berthelot JM; Puechal X; Tavernier C; Maillefert JF;
    Ann Rheum Dis; 2005 Sep; 64(9):1379-80. PubMed ID: 16100349
    [No Abstract]   [Full Text] [Related]  

  • 2. [Case report: RAEB in a patient with rheumatoid arthritis treated with methotrexate and infliximab].
    D'Alessandro G; Bianco MR; Politis S; Ferrandina C; Rossi G; Altomare E
    Reumatismo; 2006; 58(1):59-61. PubMed ID: 16639489
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment continuation in patients receiving biological agents or conventional DMARD therapy.
    Zink A; Listing J; Kary S; Ramlau P; Stoyanova-Scholz M; Babinsky K; von Hinueber U; Gromnica-Ihle E; Wassenberg S; Antoni C; Herzer P; Kekow J; Schneider M; Rau R
    Ann Rheum Dis; 2005 Sep; 64(9):1274-9. PubMed ID: 15708884
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor alpha inhibitor infliximab.
    Bendtzen K; Geborek P; Svenson M; Larsson L; Kapetanovic MC; Saxne T
    Arthritis Rheum; 2006 Dec; 54(12):3782-9. PubMed ID: 17133559
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Can very high-dose anti-tumor necrosis factor blockade at onset of rheumatoid arthritis produce long-term remission?
    Conaghan PG; Quinn MA; O'Connor P; Wakefield RJ; Karim Z; Emery P
    Arthritis Rheum; 2002 Jul; 46(7):1971-2; author reply 1973. PubMed ID: 12124886
    [No Abstract]   [Full Text] [Related]  

  • 6. Comparison of the response to infliximab or etanercept monotherapy with the response to cotherapy with methotrexate or another disease-modifying antirheumatic drug in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.
    Hyrich KL; Symmons DP; Watson KD; Silman AJ;
    Arthritis Rheum; 2006 Jun; 54(6):1786-94. PubMed ID: 16736520
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Infliximab for therapy of rheumatoid arthritis].
    Amano K
    Nihon Rinsho; 2005 Jan; 63 Suppl 1():517-20. PubMed ID: 15799410
    [No Abstract]   [Full Text] [Related]  

  • 8. Infliximab treatment of rheumatoid arthritis.
    Maini SR
    Rheum Dis Clin North Am; 2004 May; 30(2):329-47, vii. PubMed ID: 15172044
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dose escalation of infliximab therapy in arthritis patients is related to diagnosis and concomitant methotrexate treatment: observational results from the South Swedish Arthritis Treatment Group register.
    Kristensen LE; Geborek P; Saxne T
    Rheumatology (Oxford); 2009 Mar; 48(3):243-5. PubMed ID: 19106164
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Titration of infliximab treatment in rheumatoid arthritis patients based on response patterns.
    Flendrie M; Creemers MC; van Riel PL
    Rheumatology (Oxford); 2007 Jan; 46(1):146-9. PubMed ID: 16782732
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intra-articular infliximab in patients with rheumatoid arthritis and psoriatic arthritis with monoarthritis resistant to local glucocorticoids. Clinical efficacy extended to patients on systemic anti-tumour necrosis factor alpha.
    Conti F; Ceccarelli F; Priori R; Iagnocco A; Signore A; Valesini G
    Ann Rheum Dis; 2008 Dec; 67(12):1787-90. PubMed ID: 19005158
    [No Abstract]   [Full Text] [Related]  

  • 12. Therapy of patients with rheumatoid arthritis: outcome of infliximab failures switched to etanercept.
    Buch MH; Bingham SJ; Bejarano V; Bryer D; White J; Reece R; Quinn M; Emery P
    Arthritis Rheum; 2007 Apr; 57(3):448-53. PubMed ID: 17394231
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.
    Hyrich KL; Watson KD; Silman AJ; Symmons DP;
    Rheumatology (Oxford); 2006 Dec; 45(12):1558-65. PubMed ID: 16705046
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Shortening infusion times for infliximab administration.
    Buch MH; Bryer D; Lindsay S; Rees-Evans B; Fairclough A; Emery P
    Rheumatology (Oxford); 2006 Apr; 45(4):485-6. PubMed ID: 16352636
    [No Abstract]   [Full Text] [Related]  

  • 15. Sustained effect after lowering high-dose infliximab in patients with rheumatoid arthritis: a prospective dose titration study.
    van den Bemt BJ; den Broeder AA; Snijders GF; Hekster YA; van Riel PL; Benraad B; Wolbink GJ; van den Hoogen FH
    Ann Rheum Dis; 2008 Dec; 67(12):1697-701. PubMed ID: 18245109
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Infliximab in the treatment of rheumatoid arthritis].
    Akahoshi T; Watabe H
    Nihon Rinsho; 2002 Dec; 60(12):2378-83. PubMed ID: 12510365
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Should anti-tumor necrosis factor-alpha be the first therapy for rheumatoid vasculitis?
    Garcia-Porrua C; Gonzalez-Gay MA; Quevedo V
    J Rheumatol; 2006 Feb; 33(2):433; author reply 433-4. PubMed ID: 16465676
    [No Abstract]   [Full Text] [Related]  

  • 18. Responsiveness to anti-tumour necrosis factor alpha therapy is related to pre-treatment tissue inflammation levels in rheumatoid arthritis patients.
    van der Pouw Kraan TC; Wijbrandts CA; van Baarsen LG; Rustenburg F; Baggen JM; Verweij CL; Tak PP
    Ann Rheum Dis; 2008 Apr; 67(4):563-6. PubMed ID: 18042642
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Autoantibodies, metalloproteinases and bone markers in rheumatoid arthritis patients are unable to predict their responses to infliximab.
    Lequerré T; Jouen F; Brazier M; Clayssens S; Klemmer N; Ménard JF; Mejjad O; Daragon A; Tron F; Le Loët X; Vittecoq O
    Rheumatology (Oxford); 2007 Mar; 46(3):446-53. PubMed ID: 16899502
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of anti-tumor necrosis factor alpha therapy on the progression of subclinical atherosclerosis in severe rheumatoid arthritis.
    Gonzalez-Juanatey C; Llorca J; Garcia-Porrua C; Martin J; Gonzalez-Gay MA
    Arthritis Rheum; 2006 Feb; 55(1):150-3. PubMed ID: 16463428
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 14.